anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Opioids are powerful analgesics; however, their significant systemic adverse effects and the need for frequent administration restrict their use. Nalbuphine (NA) is a κ-agonist narcotic with limited adverse effects, but needs to be frequently administrated due to its short elimination half-life. Whereas sebacoyl dinalbuphine ester (SDE) is a NA prodrug, which can effectively prolong the analgesic effect, but lacks immediate pain relief. Therefore, in this study, a rapid and sustained local delivery formulation to introduce NA and SDE directly into surgical sites was developed. An amphiphilic nanostructured lipid carrier (NLC) poloxamer 407 (P407) gel (NLC-Gel) was developed to permit concurrent delivery of hydrophobic SDE from the NLC core and hydrophilic NA from P407, offering a dual rapid and prolonged analgesic effect. Benefiting from the thermal-sensitive characteristic of P407, the formulation can be injected in liquid phase and instantly transit into gel at wound site. NLC-Gel properties, including particle size, drug release, rheology, and stability, were assessed. In vivo evaluation using a rat spinal surgery model highlighted the effect of the formulation through pain behavior test and hematology analysis. NLC-Gels demonstrated an analgesic effect comparable with that of commercial intramuscular injected SDE formulation (IM SDE), with only 15 % of the drug dosage. The inclusion of supplemental NA in the exterior gel (PA12-Gel + NA) provided rapid drug onset owing to swift NA dispersion, addressing acute pain within hours along with prolonged analgesic effects. Our findings suggest that this amphiphilic formulation significantly enhanced postoperative pain management in terms of safety and efficacy.
BACKGROUND: Dectin-1 is a transmembrane receptor that plays a pivotal role in recognising fungi and Mycobacterium tuberculosis (Mtb). A specific variant, DECTIN-1 rs16910526, results in a truncated receptor that disrupts membrane expression and ligand binding and is clinically associated with recurrent cutaneous mycoses. Previous research has clarified the role of Dectin-1 in boosting immune defenses against mycobacteria by enhancing reactive oxygen species (ROS) production in neutrophils (PMNs). Here, we investigated the association between the rs16910526 variant and Dectin-1 expression in PMNs, as well as intracellular ROS production in response to Mtb. Furthermore, we explored the potential link between the rs16910526 gene variant and TB outcomes in Argentina.
METHODS: DNA was extracted from blood samples obtained from a cohort of 178 TB patients and healthy subjects (HS) in Argentina. PCR amplification and sequencing were performed to identify the rs16910526 variant. Flow cytometry was utilised to assess Dectin-1 expression on the PMN plasma membrane and to measure intracellular ROS levels, as indicated by the oxidation of DHR123 in response to the Mtb antigen.
RESULTS: PMNs carrying the rs16910526 variant exhibited diminished Dectin-1 expression and ROS production in response to Mtb (p < 0.0001). In a case‒control study, the rs16910526 variant had an allelic frequency of 0.112 in TB patients and 0.051 in HS. Notably, 10 out of 88 HS and 18 out of 62 TB patients harboured the variant (odds ratio [OR]: 2.55 [95% CI 1.1-5.9, p = 0.03]), indicating a potential association with TB disease. Furthermore, TB patients with the rs16910526 variant exhibited a delayed sputum smear conversion time (p < 0.004) and 100% positivity for acid-fast bacilli smears (p < 0.00001).
CONCLUSION: Our study identified a significant association between the SNP variant rs16910526 in the DECTIN-1 gene and Dectin-1 expression in the PMN, leading to altered ROS production. The higher frequency of this variant in TB patients compared to HS suggests a possible link with susceptibility to TB disease in Argentina.
The EUC condition will consist of a "caring message" from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, "We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you". A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts.
PURPOSE: Considering the importance of incorporating quality of life (QoL) construct during the health care of patients with stage 5 chronic kidney disease (CKD) on dialysis, it is necessary to have evidence on the clinimetric properties of the instruments used for its measurement. This study aimed to establish the clinimetric properties of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) scale in patients with stage 5 CKD on dialysis in Colombia.
METHODS: A scale validation study was conducted using the classical test theory methodology. The statistical analysis included exploratory factor analysis (EFA) and confirmatory (CFA) techniques performed on two independent subsamples; concurrent criterion validity assessments; internal consistency using four different coefficients; test-retest reliability; and sensitivity to change using mixed model for repeated measures.
RESULTS: The KDQOL-36 scale was applied to 506 patients with a diagnosis of stage 5 CKD on dialysis, attended in five renal units in Colombia. The EFA endorsed the three-factor structure of the scale, and the CFA showed an adequate fit of both the original and empirical models. Spearman's correlation coefficient values ≥0.50 were found between the domains of the CKD-specific core of the KDQOL-36 scale and the KDQ. Cronbach's alpha, McDonald's omega, Greatest lower bound (GLB), and Guttman's lambda coefficients were ≥0.89, indicating a high degree of consistency. A high level of concordance correlation was found between the two moments of application of the instrument, with values for Lin's concordance correlation coefficient ≥0.7. The application of the instrument after experiencing an event that could modify the quality of life showed statistically significant differences in the scores obtained.
CONCLUSION: The KDQOL-36 scale is an adequate instrument for measuring QoL in Colombian patients with stage 5 CKD on dialysis.
The literature suggests that zolpidem may be effective in the treatment of central sleep apnea (CSA). However, evidence regarding the efficacy of zolpidem and the underlying mechanisms involved in its effect on CSA are not well-studied. Furthermore, respiratory-related arousals are hypothesized to contribute CSA symptoms and severity. The aim of the study is to determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of the nonbenzodiazepine hypnotic zolpidem will decrease the frequency of respiratory-related arousals, lower the central apnea-hypopnea index, and widen the CO2 reserve during sleep in patients with CSA compared to no treatment. Participants will complete a night study on a low dose of zolpidem and another night study without zolpidem in a crossover manner. The order of night studies is randomized. The results will help unveil the role of arousals in CSA and the acute effect of zolpidem on CSA severity and the propensity to CSA.
Postmenopausal women are usually troubled by increasing weight and waist circumference caused by obesity and androcidal fat redistribution. Abdominal adiposity, defined as a waist circumference ≥88cm in women, measured in the upright position, plus significant elevated lipid profile values. In postmenopausal women, a higher level of physical activity was associated with a more optimal body composition, including lower adiposity and higher lean mass. Management of abdominal obesity involves different techniques i.e., dietary management, exercise therapy, even lifestyle management, and pharmacological management, and surgical interventions. Extracorporeal shockwave provides cavitation phenomena that may facilitate better management of abdominal obesity. Thus, current study will be conducted to investigate effect of extracorporeal shockwave on abdominal adiposity and lipid profile in obese post-menopausal women.
Although previous studies suggest that Piezo2 regulates chronic pain in the orofacial area, few studies have reported the direct evidence of Piezo2's involvement in inflammatory and neuropathic pain in the orofacial region. In this study, we used male Sprague Dawley rats to investigate the role of the Piezo2 pathway in the development of inflammatory and neuropathic pain. The present study used interleukin (IL)-1β-induced pronociception as an inflammatory pain model. Subcutaneous injection of IL-1β produced significant mechanical allodynia and thermal hyperalgesia. Subcutaneous injection of a Piezo2 inhibitor significantly blocked mechanical allodynia and thermal hyperalgesia induced by subcutaneously injected IL-1β. Furthermore, the present study also used a neuropathic pain model caused by the misplacement of a dental implant, leading to notable mechanical allodynia as a consequence of inferior alveolar nerve injury. Western blot analysis revealed increased levels of Piezo2 in the trigeminal ganglion and the trigeminal subnucleus caudalis after inferior alveolar nerve injury. Furthermore, subcutaneous and intracisternal injections of a Piezo2 inhibitor blocked neuropathic mechanical allodynia. These results suggest that the Piezo2 pathway plays a critical role in the development of inflammatory and neuropathic pain in the orofacial area. Therefore, blocking the Piezo2 pathway could be the foundation for developing new therapeutic strategies to treat orofacial pain conditions.
Cephalosporin suppositories were formulated from water-sol. salts of cephalosporins and >= comps. selected from among higer alc. ethers of poly(oxyethylene), and higher fatty acid esters of poly(oxyethylene). In an example, corn oil and poly(oxyethylene) lauryl ether were mixed and to this was added finely powd. cephaloridine.
Directions for method of administration are presented in Table 2.

Take a missed dose as soon as possible. If it is almost time for the next dose, skip the missed dose and take the next dose at the regular scheduled time. Do not take 2 doses at the same time.

Pantoprazole Sodium Delayed-Release Tablets

Swallow pantoprazole sodium delayed-release tablets whole, with or without food in the stomach. For patients unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed-release tablets.
OBJECTIVES: To determine the outcomes for elderly patients with de novo metastatic germ cell tumors and the influence of patient age on adherence to standard chemotherapy.
METHODS: A total of 150 patients who were initially diagnosed with metastatic germ cell tumors and treated at our institution between 2007 and 2021 were included. Patients were classified according to three age groups: aged <40, 40-49, and ≥50 years. Clinicopathological features, adherence to standard first-line chemotherapy, overall survival, and disease-free survival were compared between these groups. We also analyzed the outcomes of patients who received low-intensity induction chemotherapy due to adverse events and/or comorbidities.
RESULTS: There was no significant difference in any of the survival outcomes and in the rate of adherence to standard first-line chemotherapy between the three age groups, although elderly patients with intermediate/poor prognosis group tended to receive less-intense chemotherapies. The rate of febrile neutropenia as a chemotherapy-related adverse event was significantly higher in patients aged ≥50 years. No statistical significance in survival outcomes was detected between the group of patients who received relatively low-intensity induction chemotherapy and those who received adequately intensive planned chemotherapy.
CONCLUSIONS: The adherence rate of standard fist-line chemotherapy of elderly patients is almost comparable to that of younger patients, although some adverse events should be carefully managed. Even elderly patients with metastatic germ cell tumors can aim for equivalently good survival outcome like younger populations, with effort to adhere to standard chemotherapy.
The invention belongs to the technical field of traditional Chinese medicines, and discloses a preparation for treating beriberi and a preparation method thereof. The preparation is prepared by selecting traditional Chinese medicinal materials with rich conventional resources and mild drug effect, water and vinegar. The Chinese herbal medicines in the preparation interact with and are fused with the solvent, so that the medicinal components in the Chinese herbal medicines are combined with the solvent to achieve the effects of disinfection and sterilization, heat clearing and detoxifying, ventilation and blood stasis removal, dampness elimination and exterior syndrome relieving. The preparation can be used for effectively removing pathogenic dampness and toxic heat, and treating diseases from outside of body. The preparation provided by the above has no toxic or side effect, and is suitable for individuals of all ages. The preparation method of the preparation for treating beriberi has simple operation process flow and low requirements on the precision of the preparation device and the professional performance of operators, so the preparation method is suitable for mass production in processing plants.
Participants in this arm will wear the placebo comparator ("Clima Care" body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator ("ABDO-SYNCRO 3-BAHNIG" elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2).
Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
Oligonucleotide sequence i.e. adaptor including DNA sequence and RNA sequence can combine with TNF alpha in specificity so as to restrain damaging effect on L929 cells from TNF alpha. The invented adaptor can be utilized to test TNF alpha and cure disease caused by raised level of TNF alpha. Comparing with current antagon of TNF alpha, the invented adaptor possesses advantages of high specificity, high affinity, fast reaching target tissue and quick plasma clearance etc. The oligonucleotide sequence possesses affinity and specificity of monoclonal antibody as well as permeability and pharmacokinetics characters of small molecule polypeptide. The invention is also related to derivation sequence and modified sequence of oligonucleotide, as well as its usage, preparation and diagnosis in curing disease relevant to TNF alpha.
SARS-CoV-2, identified in Wuhan, China, in December 2019, is the third coronavirus responsible for a global epidemic, following SARS-CoV (2002) and MERS-CoV (2012). Given the recent emergence of COVID-19, comprehensive immunological data are still limited. The susceptibility and severity of SARS-CoV-2 infection are influenced by various host factors, including hormonal changes, genetic variations, inflammatory biomarkers, and behavioral attitudes. Identifying genetic factors contributing to infection severity may accelerate therapeutic development, including drug repurposing, natural extracts, and post-vaccine interventions (Initiative and Covid, 2021). This review discusses the human protein machinery involved in (a) SARS-CoV-2 host receptors, (b) the human immune response, and (c) the impact of demographic and genetic differences on individual risk for COVID-19. This review aims to clarify host factors implicated in SARS-CoV-2 susceptibility and progression, highlighting potential therapeutic targets and supportive treatment strategies.
PURPOSE:To prepare the titled inhibiting agent effective as a hypotensor having little side effect, by decomposing bovine-originated casein with a digestive enzyme, trypsin. CONSTITUTION:Bovine-originated casein is decomposed with trypsin at 5.0- 9.0pH. The decomposition product is heated at 100 deg.C or treated with an acid to precipitate the trypsin and undecomposed casein. The precipitate is removed by centrifugal separation, etc., and the resultant mother liquid is neutralized with an alkali such as sodium hydroxide, and concentrated to 1/2-1/3 of the original volume. The angiotensinase inhibitor of the formula can be prepared by purifying the concentrated liquid. The inhibitor is administered by the intravenous injection of its aqueous solution at a dose of 0.01-10mg/kg.
BACKGROUND: The burden of cervical cancer in Ghana is high due to a lack of a national screening and vaccination program. Geographical variations in high-risk Human Papilloma Virus incidence and type should be considered for vaccine improvement and screening in LMICs.
METHODS: A descriptive, multi-center cross-sectional study with purposive sampling of cases with cervical cancer diagnosed from January 2012 through to December 2018 was employed relying on archived Formalin Fixed Paraffin Embedded (FFPE) tissues from four (4) Teaching Hospitals. Cervical cancers were assessed for histopathological features following WHO guidelines. In addition, the novel Tumour Budding and Nest Size Grade (TBNS) for SCC, SILVA pattern of invasion for EAC and Tumour Infiltrating Lymphocytes (TILs) were assessed. High Risk HPV testing was performed using an isothermal, multiplex nucleic acid amplification method from ATILA biosystem (Mountain View California, USA). The FFPE blocks were tested for 15 hrHPV genotypes. Results were analyzed using SPSS v.26.0, with descriptive statistics and cross-tabulation and chi-square tests done with significance established at p < 0.05.
RESULTS: A total of 297 cases were identified for the study with ages ranging from 20 to 95 years. The peak age group for cervical cancer was 46 to 55 years. For those tested, hrHPV positivity rate was 85.4% [EAC (84.6%) and SCC (85.6%)]. The top five hrHPV serotypes for both histological cancers were 59 (40.0%), 35 (32.0%), 18 (30.0%), 16 (15.0%), and 33 (10.0%) respectively. Approximately, 58.2% of infections were multiple. Single hrHPV infections were mostly caused by hrHPV 59 (28.9%), and 16 (26.3%). TBNS grade for SCC, SILVA pattern of invasion for EAC and TILs did not show any statistically significant relationship with hrHPV.
CONCLUSION: We affirm reported differences in hrHPV types associated with cervical cancer in Ghana with hrHPV types such as 59, 35, and 33 forming a significant proportion of hrHPV types associated with cervical cancer. This difference in hrHPV types should guide vaccine improvement and triaging of hrHPV positives. Though multiple infections are more common, some hrHPV types such as hrHPV 16 and 59 are responsible for most single infections associated with cervical cancer. Simple haematoxylin and eosin-based morphological assessments can improve the prognostication of patients with cervical cancer.
The invention discloses a recombinant protein containing Cap of classical swine fever E2 and circovirus, a preparation method and application thereof, and belongs to the field of vaccines. The active component of the vaccine disclosed by the invention is recombinant protein, the recombinant protein is formed by connecting fusion proteins CSFVE2-Spycatcher and Cap-SpyTag, and the fusion proteins CSFVE2-Spycatcher is protein with an amino acid sequence of SEQ ID No. 2; the fusion protein Cap-SpyTag is a protein with an amino acid sequence of SEQ ID No. 3. The invention also provides a construction method for co-expressing the swine fever E2 in the CHO cell strain, which utilizes circular VLPs to display E2, achieves the conversion of E2 VLPs, can improve the immunogenicity of E2 antigen, achieves mutual stimulation immunity, and improves the protective effects of swine fever and circular immunity. The invention improves the defects that the expressing product of the swine fever E2 protein in a mammalian cell has poor immune effect, and the expressing product of the swine fever E2 protein in a prokaryotic expression system can lead the swine to generate short antibody time and cause immune death by prokaryotic endotoxin residue after the swine is immunized.
PURPOSE: A composition containing ameloblast, apical bud cells, or a culture thereof is provided to enhance DSPP promoter and to induce regeneration of dental pulp. CONSTITUTION: A pharmaceutical composition for regenerating dentin or dental pulp contains ameloblast or culture thereof as an active ingredient. The ameloblast is ameloblast-lineage cells. A pharmaceutical composition for regenerating dentin or dental pulp contains apical bud cells or culture thereof as an active ingredient. The culture is prepared by culturing the apical bud cells for 3-7 days. A pharmaceutical composition for promoting hard tissue formation contains the ameloblast or culture liquid thereof as an active ingredient.
Do you the invention discloses a kind of compd A spochalasin? V and its preparation method and application, described compd A spochalasin? the structure of V is as shown in formula I, described preparation method, comprising: accessed in substratum by aspergillus flavipes CCTCC2013631 and carry out fermentation culture; After fermentation culture, be separated and obtain fermented liquid, with organic solvent, fermented liquid is extracted, be extracted liquid; Successively through normal phase silica gel chromatography post and high performance liquid chromatography separation and purification after described extraction liquid is concentrated, the compd A spochalasin described in acquisition? V.Do you the invention also discloses described compd A spochalasin? V is preparing the application in antitumor drug or tumor prevention protective foods.Compd A spochalasin of the present invention? V has anti-tumor activity, and preparation method is easy, easy handling, low production cost, is applicable to large-scale production.
PURPOSE:A foamable bathing agent obtained by blending a carbonate with an organic acid to give a foamable bathing composition and mixing the composition with polyethylene glycol and macrogol as a stabilizer. CONSTITUTION:5-80wt% carbonate (e.g. dried NaHCO3, Na2CO3, etc.) is blended with 10-200wt% organic acid (e.g. succinic acid, citric acid, etc.) to give a foamable bathing composition, which is mixed with 0.5-20wt% based on the whole composition of polyethylene glycol and 5-15wt% macrogol 6,000 especially preferably having fine molecules to give a foamable bathing agent. Further the agent is blended with one or more of perfume, dyestuff, vitamins, active ingredients of hot spring, protease, etc., selectively a binder, a disintegrator, lubricant, vehicle, etc., besides the above-mentioned essential components and formed into powder or solid state. The agent is packed with a waterproof packaging material (e.g. metallic laminate film, etc.) before use or stored in a closed container.